MOUNTAIN VIEW, Calif. (October 30, 2006) – Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first and only non-incisional permanent birth control method available, today announced that Gregory Lichtwardt, Conceptus’ chief financial officer, will present at the CIBC World Markets 17th Annual Healthcare Conference on Tuesday, November 7, 2006, at 8:00 AM Eastern Time. The conference will be held at the Waldorf-Astoria Hotel in New York City from November 6 through November 8, 2006.

Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Conceptus’ web site www.conceptus.com a few minutes prior to start time to download any necessary software.

The CIBC World Markets Healthcare Conference brings together over 1,500 leaders in the pharmaceutical, biotechnology, medical device, and healthcare service arenas.

Update on C.E. Unterberg Towbin Conference Attendance
Due to a scheduling conflict, Mark Sieczkarek, Conceptus’ chief executive officer, has cancelled his presentation at the C.E. Unterberg Towbin Life Sciences Investor Conference scheduled for October 31, 2006 at 10am Eastern at the Palace Hotel in New York City.

About the Essure Procedure
The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80% effective after four years of follow-up. The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective based on 5 years of follow-up. Five year follow-up of all patients in clinical trials is ongoing.

About Conceptus
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.